loading...

Home

About PHDHS

Neurobiology and Disease

Organizers: Ana Cristina Rego, Cláudia PereiraPaula Moreira and Sandra Cardoso

The course schedule can be found here

Background and goals

Neurodegenerative disorders affect selective brain regions and are associated with the formation of insoluble protein aggregates. These disorders are also characterized by a gradual progression of symptoms that commonly result in dementia and finally the death of the patients. However, the mechanisms by which altered proteins initiate the pathogenic processes linked to these diseases remains to be elucidated. The development of animal models for neurodegenerative disorders has given important insights into the mechanisms of toxicity, being also useful for testing potential effective therapies. Indeed, currently there is no cure for these devastating disorders; however, new treatments are on the horizon as a result of accelerating knowledge into the intricate biology of these diseases.

The PhD course on ‘Neurobiology and Disease’ will focus on the latest research in the field of neurodegenerative diseases, affecting both central and peripheral nervous system, including Alzheimer’s disease (AD), Parkinson’s disease (PD), polyglutamine (polyQ) expansion diseases (e.g. Machado-Joseph disease (MJD) and Huntington’s disease (HD)) and familial amyloid polyneuropathy (FAP). The course is intended to promote the understanding of molecular, biochemical and cellular mechanisms operating in these devastating diseases and their correlation with clinical alterations. Furthermore, the course will cover novel detection methods and therapies that are under development. Clinical and neuropathological aspects of these disorders will be discussed by clinical physicians.




Faculty affiliations:
Patrik Verstreken (PhD) - VIB Center for Biology of Disease, Katholieke Universiteit Leuven, Leuven,
Belgium
E-mail:

Ernest Arenas (MD, PhD) - Karolinska Institute, Department of Medical Biochemistry and Biophysics,
Division of Molecular Neurobiology, Stockholm, Sweden
E-mail:

Maria João Saraiva (PhD) - Institute of Molecular and Cellular Biology (IBMC), University of Porto, Porto,
Portugal
E-mail: mjsaraiv@ibmc.up.pt


Inês Baldeiras PhD) - Laboratory of Neurochemistry

University Hospital of Coimbra (HUC), Neurology Service, Faculty of

Medicine, University of Coimbra, Coimbra, Portugal

E-mail: ines.baldeiras@sapo.pt


Patrícia Maciel (PhD) - ICVS - Life and Health Sciences Research Institute, University of Minho, Braga,
Portugal
E-mail: pmaciel@ecsaude.uminho.pt

Joaquim Ferreira (MD) – ‘Instituto de Medicina Molecular’ (IMM), Faculty of Medicine, University of
Lisbon, Lisbon, Portugal
E-mail: jferreira@fm.ul.pt

Isabel Santana (MD, PhD) - University Hospital of Coimbra (HUC), Neurology Service, Faculty of
Medicine, University of Coimbra, Coimbra, Portugal
E-mail: isabeljsantana@gmail.com

Cristina Januário (MD, PhD) - University Hospital of Coimbra (HUC), Neurology Service, Faculty of
Medicine, University of Coimbra, Coimbra, Portugal
E-mail: cristinajanuario@gmail.com

Paula I. Moreira (PhD) - Center for Neuroscience and Cell Biology, Faculty of Medicine, University of
Coimbra, Coimbra, Portugal
E-mail : pismoreira@gmail.com; paula.moreira@fmed.uc.pt

Sandra M. Cardoso (PhD) - Center for Neuroscience and Cell Biology, Faculty of Medicine, University of
Coimbra, Coimbra, Portugal
E-mail: cardoso.sandra.m@gmail.com

Cláudia F. Pereira (PhD) - Center for Neuroscience and Cell Biology, Faculty of Medicine, University of
Coimbra, Coimbra, Portugal
E-mail: claudia.mf.pereira@gmail.com; cpereira@fmed.uc.pt

Ana Cristina Rego (PhD) - Center for Neuroscience and Cell Biology, Faculty of Medicine, University of
Coimbra, Coimbra, Portugal
E-mail: a.cristina.rego@gmail.com; acrego@cnc.uc.pt; arego@fmed.uc.pt




References:

Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 10(9):698-712.
Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF (2010) Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets. 11(10):1193-206.
Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci. 27(11):2803-20. Erratum in: Eur J Neurosci. 2008;28(10):2156.
Arduíno DM, Esteves AR, Oliveira CR, Cardoso SM (2010) Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease. CNS Neurol Disord Drug Targets. 9(1):105-19.